Clinical Analysis of Alpharadin to be Presented at the 2011 Annual Meeting of the American Society of Clinical Oncology
News Jun 06, 2011
Algeta ASA has announced that an analysis of clinical data from its phase II clinical program with Alpharadin will be presented at the 2011 ASCO Annual Meeting in Chicago, Illinois, USA (3-7 June 2011).
The analysis concluded that the ALP normalization caused by Alpharadin (radium-223) in patients with bone metastases from castration-resistant prostate cancer (CRPC) was associated with a significant improvement in overall survival.
Poster title: Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223.
The cholesterol-lowering drugs called statins have demonstrated substantial benefits in reducing the risk of heart attacks and strokes caused by blood clots (ischemic strokes) in at-risk patients. Since statins are associated with a low risk of side effects, the benefits of taking them outweigh the risks, according to a scientific statement from the American Heart Association that reviewed multiple studies evaluating the safety and potential side effects of these drugs.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019